1. "2018"
Formats
  1. Journal Article (3011)
  2. Meeting Abstract (1948)
  3. Book Section (206)
  4. Conference Paper (38)
  5. Book Whole (11)
  6. Editorial (4)
  7. Review (4)
  8. Miscellaneous (2)
  9. Correspondence (1)
Groups
  1. Department of Medicine (2296)
  2. Solid Tumor Oncology Division (1378)
  3. GSK Faculty (1136)
  4. Sloan Kettering Institute Postdocs (1044)
  5. Surgery (870)
  6. Center for Hematologic Malignancies (863)

More Groups

People
  1. Sergio Giralt (87)
  2. Matthew Hellmann (78)
  3. Jedd Wolchok (74)
  4. Marc Ladanyi (74)
  5. Robert Motzer (71)
  6. Nancy Lee (64)

More People

Years
  1. 2018 (5225)
Publications
  1. Journal of Clinical Oncology (562)
  2. Blood (249)
  3. Cancer Research (183)
  4. Annals of Oncology (140)
  5. International Journal of Radiation Oncology, Biology, Physics (137)
  6. Modern Pathology (127)

More Publications

Publishers
  1. Elsevier Inc. (691)
  2. American Society of Clinical Oncology (605)
  3. Springer (410)
  4. American Association for Cancer Research (299)
  5. Oxford University Press (291)
  6. American Society of Hematology (273)

More Publishers

Results (5225)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer
    Meeting Abstract

    Modi, S.; Pusztai, L.; Forero, A.; Mita, M.; Miller, K. D.; Weise, A.; Krop, I.; Burris, H. 3rd; Kalinsky, K.; Tsai, M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers
    Meeting Abstract

    Modi, S.; Tsurutani, J.; Takahashi, S.; Iwata, H.; Park, H.; Redfern, C. H.; Doi, T.; Li, B.; Iwasa, T.; Taira, S.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Novel driver genetic alterations in MYB-NFIB-negative breast adenoid cystic carcinomas
    Meeting Abstract

    Kim, J.; Geyer, F. C.; Martelotto, L. G.; Ng, C. K. Y.; Lim, R. S.; Selenica, P.; Li, A.; Pareja, F.; Fusco, N.; Edelweiss, M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial
    Meeting Abstract

    Sotiriou, C.; Rothé, F.; Maetens, M.; Fumagalli, D.; Brown, D. N.; Salgado, R.; Bradbury, I.; Pusztai, L.; Harbeck, N.; Ignatiadis, M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer
    Meeting Abstract

    Sparano, J. A.; O'Neill, A.; Alpaugh, K.; Wolff, A. C.; Northfelt, D. W.; Dang, C.; Sledge, G. W. Jr.; Miller, K. D.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Immune profile of small HER2+ tumors in the APT trial
    Meeting Abstract

    Tolaney, S. M.; Barry, W.; Guo, H.; Dillon, D.; Tan, Y. B.; Fuhrman, K.; Osmani, W.; Getz, A.; Baltay, M.; Dang, C.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
    Meeting Abstract

    Tripathy, D.; Sara, T.; Seidman, A. D.; Anders, C. K.; Ibrahim, N.; Rugo, H. S.; Twelves, C. J.; Diéras, V.; Müller, V.; Hannah, A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial
    Meeting Abstract

    Venet, D.; Rothé, F.; Dupont, F.; Maetens, M.; Fumagalli, D.; Salgado, R.; Bradbury, I.; Pusztai, L.; Harbeck, N.; Izquierdo, M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Does breast density increase the risk of re-excision for women with breast cancer having breast conservation therapy?
    Meeting Abstract

    Walsh, S. M.; Brennan, S. B.; Zabor, E.; Rosenberger, L. H.; Stempel, M.; Lebron-Zapata, L.; Gemignani, M. L.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer
    Meeting Abstract

    Smyth, L. M.; Oliveira, M.; Ciruelos, E.; Tamura, K.; El-Khoueiry, A.; Mita, A.; You, B.; Renouf, D. J.; Sablin, M. P.; Lluch, A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save